Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)

Prerandomization Inclusion Criteria:

• Provide written informed consent before initiation of any study related procedures.

• Be at least 18 years of age

• Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary ArteryBypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery,and/or valve replacement/repair surgery

Prerandomization Exclusion Criteria:

• Women of child-bearing potential (unless they have a negative pregnancy test)

• Recent cerebrovascular accident (within 3 months before randomization)

• Known intolerance to calcium channel blockers

• Known or suspected hypersensitivity to nicardipine

• Allergy to soybean oil or egg lecithin (components of the lipid vehicle)

• Pre-existing permanent ventricular pacing

• Any other disease or condition, which, in the judgment of the investigator would placea patient at undue risk by being enrolled in the trial

• Participation in another therapeutic drug or therapeutic device trial within 30 daysof starting study Postrandomization Inclusion Criteria:

• Expected to survive beyond 24 hours post-surgical procedure

• No surgical complications or conditions, present or anticipated, that preclude themfrom inclusion in the study

• Determined to be hypertensive postoperatively as determined by the investigator